www.tickerreport.com ·
inhibrx biosciences nasdaqinbx releases quarterly earnings results misses estimates by 0 47 eps
Topic context
This topic has been covered 241611 times in the last 30 days across our monitored publishers.
The full article is on the original publisher site. This page only shows the headline and a very short excerpt.
AI insight
AI-generatedSingle-company earnings miss for Inhibrx Biosciences (NASDAQ: INBX), a biotech firm. The EPS miss of $0.47 is a direct negative signal for the company's profitability and near-term margin outlook. No broader sector or supply-chain impact; the mechanism is company-specific earnings disappointment. No scarcity, demand spike, or regulatory channel identified.
Signals our AI researcher identified
Extracted by our AI model from this article and related public sources — not direct quotes from the publisher.
- Inhibrx Biosciences reported Q1 2026 loss of $2.15 per share, missing consensus of $1.68 by $0.47.
- Shares fell 1.5% to $116.16 on the earnings miss.
- Market cap is $1.70 billion; debt-to-equity ratio is 12.58.
- Institutional ownership is 82.46%.
- Analyst consensus rating is 'Hold' with average price target of $150.00.
Inhibrx Biosciences shares are expected to decline 1-3% in the next 48 hours due to a Q1 2026 EPS miss of $0.47.
Sign in to see all sector verdicts, full thesis and counter-argument debate.
Sector impact at a glance
- PHARMA_BIOTECHmid
- PHARMA_BIOTECHshort
